Alan P. Venook, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
venook_alan

Professor, Department of Medicine (Hematology/Oncology), UCSF
Madden Family Distinguished Professorship in Medical Oncology and Translational Research, UCSF

Phone: (415) 353-9888 (appts)
Box 1705, UCSF
San Francisco, CA 94143-1705

View on UCSF Profiles


Additional Websites


Education

Rutgers College, New Brunswick, New Jersey, BA, 1976, Biological Sciences
University of California San Francisco, MD, 1980, Medicine
University of California San Francisco, Internship, 1981, Internal Medicine
University of California, Davis, Residency, 1985, Internal Medicine
University of California San Francisco, Fellowship, 1987, Hematology/Oncology


Professional Experience

  • 1980
    Assistant Clinical Professor of Medicine, UCSF
  • 1994-2000
    Associate Professor of Clinical Medicine, UCSF
  • 1997-2004
    Director, Clinical Research Support Services Core, UCSF Comprehensive Cancer Center
  • 2004-2007
    Associate Chief, Division of Medical Oncology, UCSF
  • 2004- present
    Member, Executive Policy Group of the Human Research Protection Program
  • 2005-present
    Chairman, UCSF Committee on Human Research
  • 2005-present
    Chairman, Cancer Center Data Safety Monitoring Committee
  • 2008- 2010
    Director, Regulatory Knowledge and Support Program of the UCSF Clinical and Translational Science Institute
  • 2008-present
    Member, Research Administration Board
  • 2000-present
    Professor of Clinical Medicine, UCSF

Honors & Awards

  • 1999
    Mention-Colon Cancer-Medical Oncologist, Top Cancer Specialsts, Good Housekeeping
  • 1999
    Mention-Medical Oncology and Hematology, Top 425 Doctors in the Bay Area, San Francisco

Selected Publications

  1. Venook AP, Arcila ME, Benson AB, Berry DA, Camidge DR, Carlson RW, Choueiri TK, Guild V, Kalemkerian GP, Kurzrock R, Lovly CM, McKee AE, Morgan RJ, Olszanski AJ, Redman MW, Stearns V, McClure J, Birkeland ML. NCCN Working Group Report: Designing Clinical Trials in the Era of Multiple Biomarkers and Targeted Therapies. J Natl Compr Canc Netw. 2014 Nov; 12(11):1629-49.
    View on PubMed
  2. Van Loon K, Owzar K, Jiang C, Kindler HL, Mulcahy MF, Niedzwiecki D, O'Reilly EM, Fuchs C, Innocenti F, Venook AP. 25-Hydroxyvitamin D Levels and Survival in Advanced Pancreatic Cancer: Findings From CALGB 80303 (Alliance). J Natl Cancer Inst. 2014 Aug; 106(8).
    View on PubMed
  3. Benson AB, D'Angelica MI, Abrams TA, Are C, Bloomston PM, Chang DT, Clary BM, Covey AM, Ensminger WD, Iyer R, Kelley RK, Linehan D, Malafa MP, Meranze SG, Park JO, Pawlik T, Posey JA, Scaife C, Schefter T, Sigurdson ER, Tian GG, Vauthey JN, Venook AP, Yen Y, Zhu AX, Hoffmann KG, McMillian NR, Sundar H. Hepatobiliary cancers, version 2.2014. J Natl Compr Canc Netw. 2014 Aug; 12(8):1152-82.
    View on PubMed
  4. Benson AB, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, Messersmith W, Mulcahy MF, Murphy JD, Nurkin S, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Freedman-Cass DA. Colon cancer, version 3.2014. J Natl Compr Canc Netw. 2014 Jul; 12(7):1028-59.
    View on PubMed
  5. Fuchs MA, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Wu K, Willett WC, Giovannucci EL, Meyerhardt JA. Sugar-Sweetened Beverage Intake and Cancer Recurrence and Survival in CALGB 89803 (Alliance). PLoS One. 2014; 9(6):e99816.
    View on PubMed
  6. Fidelman N, Kerlan RK, Hawkins RA, Taylor AG, Kohi MP, Kolli KP, Bergsland EK, Kelley RK, Ko AH, Korn WM, McWhirter RM, Luan J, Venook AP. (90)Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study. J Gastrointest Cancer. 2014 Jun; 45(2):168-80.
    View on PubMed
  7. Shiovitz S, Bertagnolli MM, Renfro LA, Nam E, Foster NR, Dzieciatkowski S, Luo Y, Lao VV, Monnat RJ, Emond MJ, Maizels N, Niedzwiecki D, Goldberg RM, Saltz LB, Venook A, Warren RS, Grady WM. CpG Island Methylator Phenotype Is Associated With Response to Adjuvant Irinotecan-Based Therapy for Stage III Colon Cancer. Gastroenterology. 2014 Sep; 147(3):637-45.
    View on PubMed
  8. Carlson RW, Larsen JK, McClure J, Fitzgerald CL, Venook AP, Benson AB, Anderson BO. International Adaptations of NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2014 May 1; 12(5):643-8.
    View on PubMed
  9. Mayer RJ, Venook AP, Schilsky RL. Progress Against GI Cancer During the American Society of Clinical Oncology's First 50 Years. J Clin Oncol. 2014 May 20; 32(15):1521-30.
    View on PubMed
  10. Ellis LM, Bernstein DS, Voest EE, Berlin JD, Sargent D, Cortazar P, Garrett-Mayer E, Herbst RS, Lilenbaum RC, Sima C, Venook AP, Gonen M, Schilsky RL, Meropol NJ, Schnipper LE. American society of clinical oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014 Apr 20; 32(12):1277-80.
    View on PubMed
  11. Van Loon K, Venook AP. Curable patient with metastatic colorectal cancer: balancing effective therapies and toxicities. J Clin Oncol. 2014 Apr 1; 32(10):991-6.
    View on PubMed
  12. Venook AP, Weiser MR, Tepper JE. Colorectal cancer: all hands on deck. Am Soc Clin Oncol Educ Book. 2014; 34:83-9.
    View on PubMed
  13. Nixon AB, Pang H, Starr MD, Friedman PN, Bertagnolli MM, Kindler HL, Goldberg RM, Venook AP, Hurwitz HI. Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance). Clin Cancer Res. 2013 Dec 15; 19(24):6957-66.
    View on PubMed
  14. Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer. 2013 Oct 1; 109(7):1725-34.
    View on PubMed
  15. Jeon J, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Wigler DS, Atienza D, Messino M, Kindler H, Venook A, Fuchs CS, Meyerhardt JA. Impact of Physical Activity After Cancer Diagnosis on Survival in Patients With Recurrent Colon Cancer: Findings From CALGB 89803/Alliance. Clin Colorectal Cancer. 2013 Dec; 12(4):233-8.
    View on PubMed
  16. Van Loon K, Venook AP. Biomarkers in colon cancer: the chasm between expectations and reality. Oncology (Williston Park). 2013 Aug; 27(8):758, 763.
    View on PubMed
  17. Abou-Alfa GK, Venook AP. The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached? Lancet Oncol. 2013 Jun; 14(7):e283-8.
    View on PubMed
  18. Benson AB, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W, Sofocleous CT, Venook AP, Willett CG, Gregory KM, Freedman-Cass DA. Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013 May 1; 11(5):519-28.
    View on PubMed
  19. Maru D, Venook AP, Ellis LM. Predictive biomarkers for bevacizumab: are we there yet? Clin Cancer Res. 2013 Jun 1; 19(11):2824-7.
    View on PubMed
  20. Venook AP, Niedzwiecki D, Lopatin M, Ye X, Lee M, Friedman PN, Frankel W, Clark-Langone K, Millward C, Shak S, Goldberg RM, Mahmoud NN, Warren RS, Schilsky RL, Bertagnolli MM. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. J Clin Oncol. 2013 May 10; 31(14):1775-81.
    View on PubMed

Go to UCSF Profiles, powered by CTSI